The impact of direct acting antivirals on hepatitis C virus disease burden and associated costs in four european countries.
Francesco Saverio MenniniAndrea MarcellusiSarah Robbins ScottSimona MontillaLoreta A KondiliMaria Buti FerretLiana GheorgheStephen D RyderLoreta Anesti KondiliPublished in: Liver international : official journal of the International Association for the Study of the Liver (2021)
Direct-acting antivirals have significant clinical benefits and can bring substantial cost-savings over the next 20 years, reaching a Break-even point in a short period of time. When pursuing an exit strategy from strict lockdown measures for COVID-19, providing DAAs should remain high on the list of priorities in order to maintain HCV elimination efforts.